Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 5:09 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2185–2208 of 2,516 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Sequence Clear all
Completed Not applicable Interventional Accepts healthy volunteers Results available

Evaluation of ACUVUE® OASYS 1-Day for Astigmatism Contact Lenses With Alternative Lidstock

NCT05713552
View directory record Official record
Conditions
Ocular Physiology
Interventions
Acuvue Oasys 1 Day for Astigmatism with Legacy lidstock, Acuvue Oasys 1 Day for Astigmatism with Amcor laminated lidstock
Device
Lead sponsor
Johnson & Johnson Vision Care, Inc.
Industry
Eligibility
18 Years to 39 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Mar 5, 2024 · Synced Nov 14, 2026, 5:09 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Diazepam After Intranasal and Intravenous Administration to Healthy Volunteers

NCT01364558
View directory record Official record
Conditions
Epilepsy
Interventions
Diazepam
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 45 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 1, 2019 · Synced Nov 14, 2026, 5:09 AM EST
Completed Phase 4 Interventional Results available

An Efficacy Study of Umeclidinium/Vilanterol With Tiotropium/Olodaterol in COPD Patients

NCT02799784
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
UMEC/VI, TIO/OLO, Albuterol/salbutamol
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
9
States / cities
Clearwater, Florida • Orlando, Florida • St Louis, Missouri + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2018 · Synced Nov 14, 2026, 5:09 AM EST
Completed Not applicable Interventional

Assertive Community Treatment With CBT and SST for Schizophrenia

NCT02254733
View directory record Official record
Conditions
Schizophrenia
Interventions
Cognitive Behavioral Social Skills Training (CBSST), Assertive Community Treatment (ACT)
Behavioral · Other
Lead sponsor
Veterans Medical Research Foundation
Other
Eligibility
18 Years and older
Enrollment
178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Nov 17, 2016 · Synced Nov 14, 2026, 5:09 AM EST
Recruiting Early Phase 1 Interventional

A Phase 0/1 Study of cDNA for TP53, Checkpoint Inhibition and Radiation in Children With Recurrent, Progressive or Refractory CNS Malignancies.

NCT07017816
View directory record Official record
Conditions
CNS Malignancies, Medulloblastoma Recurrent, ATRT Recurrent, Pineoblastoma, Embryonal Neoplasm, Ependymoma Recurrent, High Grade Gliomas
Interventions
SGT-53, hypofractionated radiotherapy with immunotherapy, Nivolumab
Drug · Radiation
Lead sponsor
Children's National Research Institute
Other
Eligibility
3 Years to 21 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Nov 14, 2026, 5:09 AM EST
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Reduction in Pain Intensity Following IV or Oral Pain-relieving Products

NCT02678416
View directory record Official record
Conditions
Pain
Interventions
IV Acetaminophen (Treatment A), Oral Acetaminophen (Treatment B), Placebo (Treatment C), Morphine (Treatment D)
Drug · Other
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
79 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Feb 5, 2020 · Synced Nov 14, 2026, 5:09 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Phenytoin or Itraconazole on How BGB-16673 is Absorbed and Removed From the Body in Healthy Participants

NCT06906809
View directory record Official record
Conditions
Healthy Volunteers
Interventions
BGB-16673, Itraconazole, Phenytoin
Drug
Lead sponsor
BeiGene
Industry
Eligibility
18 Years to 65 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Nov 14, 2026, 5:09 AM EST
Not yet recruiting Not applicable Interventional

Osteopathic Manipulative Treatment for Children With Chronic or Recurrent Otitis Media

NCT07639775
View directory record Official record
Conditions
Otitis Media, Otitis Media Effusion, Otitis Media Recurrent, Otitis Media With Effusion in Children, Otitis Media Chronic, Otitis Media in Children, Tympanostomy Tube Insertion, Osteopathic Manipulative Treatment (OMT)
Interventions
Experimental Osteopathic Manipulative Treatment (OMT) Protocol, Control Osteopathic Manipulative Treatment (OMT) Protocol
Other
Lead sponsor
Sarah Vidal
Other
Eligibility
6 Months to 6 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Lynchburg, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Nov 14, 2026, 5:09 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic Study of SP-103 in Healthy Adult Human Subjects

NCT04819581
View directory record Official record
Conditions
Healthy
Interventions
SP-103, ZTlido
Drug
Lead sponsor
Scilex Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Dilworth, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 29, 2021 · Synced Nov 14, 2026, 5:09 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess the Effect of Branebrutinib on the Drug Levels of Rosuvastatin in Healthy Participants

NCT04515628
View directory record Official record
Conditions
Healthy Participants
Interventions
Rosuvastatin, Branebrutinib
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 50 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 10, 2022 · Synced Nov 14, 2026, 5:09 AM EST
Recruiting No phase listed Observational Accepts healthy volunteers

Heart Transplantation - Renewal

NCT05521399
View directory record Official record
Conditions
Transplant, Heart, Magnetic Resonance Imaging
Interventions
MRI Sequencing, MRI Testing (pediatric), MRI Testing
Diagnostic Test
Lead sponsor
Northwestern University
Other
Eligibility
Not listed
Enrollment
247 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2030
U.S. locations
2
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced Nov 14, 2026, 5:09 AM EST
Active, not recruiting Not applicable Interventional

Transcranial Direct Current Stimulation of the Temporal Cortex in Survivors of Childhood Acute Lymphoblastic Leukemia (ALL)

NCT04105530
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Transcranial Direct Current Stimulation, Executive Dysfunction
Interventions
Anodal tDCS treatment, Cathodal tDCS treatment, Sham treatment, NIH Toolbox List Sorting Working Memory Test, NIH Toolbox Flanker Inhibitory Control and Attention Test, Grooved Peg Board Test, Buschke Selective Reminding Test
Device · Other
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
8 Years to 215 Months
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 12, 2024 · Synced Nov 14, 2026, 5:09 AM EST
Withdrawn Not applicable Interventional

Brief CBT for the Treatment of Depression During Inpatient Hospitalization

NCT03011619
View directory record Official record
Conditions
Depression
Interventions
Usual Standard of Care, Cognitive Behavioral Therapy Condition (CBT)
Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 26, 2019 · Synced Nov 14, 2026, 5:09 AM EST
Completed Phase 1 Interventional

A Study to Determine the Effect of Food on the Pharmacokinetics of PCI-32765

NCT01820936
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Sequence 1: PCI-32765, Sequence 2: PCI-32765, Sequence 3: PCI-32765, Sequence 4: PCI-32765, Sequence 5: PCI-32765
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Neptune City, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 15, 2014 · Synced Nov 14, 2026, 5:09 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Impact of Itraconazole on the Pharmacokinetics and Safety of Dazucorilant in Healthy, Adult Participants

NCT06495944
View directory record Official record
Conditions
Healthy Adults
Interventions
Dazucorilant, Itraconazole
Drug
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
18 Years to 60 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2025 · Synced Nov 14, 2026, 5:09 AM EST
Recruiting Not applicable Interventional Accepts healthy volunteers

Nutrition for Precision Health, Powered by the All of Us

NCT05701657
View directory record Official record
Conditions
Nutrition, Health, Dietary Habits
Interventions
Diet A, Diet B, Diet C
Other
Lead sponsor
RTI International
Other
Eligibility
18 Years and older
Enrollment
8,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
14
States / cities
Birmingham, Alabama • Davis, California • Los Angeles, California + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Nov 14, 2026, 5:09 AM EST
Recruiting Phase 1Phase 2 Interventional

Precision Microbiota Interventions for Senoreduction Trial

NCT07462767
View directory record Official record
Conditions
HIV Infections, Alcohol Drinking, Aging, Immunosenescence
Interventions
Limosilactobacillus reuteri, Blueberry extract
Dietary Supplement
Lead sponsor
Louisiana State University Health Sciences Center in New Orleans
Other
Eligibility
40 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Oct 29, 2026 · Synced Nov 14, 2026, 5:09 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Effect Of Itraconazole On The Pharmacokinetics Of Palbociclib

NCT02131298
View directory record Official record
Conditions
Healthy
Interventions
Palbociclib Alone, Palbociclib plus itraconazole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 30, 2014 · Synced Nov 14, 2026, 5:09 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of LY3202626 in Healthy Participants and Participants With Alzheimer's Disease

NCT02323334
View directory record Official record
Conditions
Healthy Volunteers, Alzheimer Disease
Interventions
LY3202626, Placebo (Part A, B, C), Itraconazole
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
20 Years and older
Enrollment
94 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Apr 19, 2021 · Synced Nov 14, 2026, 5:09 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Ipatasertib (GDC-0068) Study to Evaluate Formulation Change and Food Effect on Bioavailability in Healthy Subjects

NCT02536391
View directory record Official record
Conditions
Cancer
Interventions
Ipatasertib (capsule), Ipatasertib (tablet)
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Nov 14, 2026, 5:09 AM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

Pilot Dispensing Study of Two Marketed Daily Disposable Multifocal Contact Lenses

NCT07076160
View directory record Official record
Conditions
Visual Acuity, Presbyopia
Interventions
INFUSE® One Day Multifocal, ACUVUE® OASYS MAX 1-Day Multifocal Contact Lens
Device
Lead sponsor
Johnson & Johnson Vision Care, Inc.
Industry
Eligibility
40 Years to 70 Years
Enrollment
74 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
7
States / cities
Jacksonville, Florida • Longwood, Florida • Maitland, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Nov 14, 2026, 5:09 AM EST
Completed Not applicable Interventional

Clinical Evaluation of a Device for Treatment of Lymphedema of the Upper Extremity

NCT06407791
View directory record Official record
Conditions
Lymphedema, Lymphedema Arm, Lymphedema of Upper Arm
Interventions
LymphaVibe
Device
Lead sponsor
Carilion Clinic
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Roanoke, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Nov 14, 2026, 5:09 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Phase 1 Study of ALXN1840 on the Metabolism of a CYP2C9 Substrate in Healthy Participants.

NCT04526197
View directory record Official record
Conditions
Wilson Disease
Interventions
ALXN1840, Celecoxib
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 21, 2023 · Synced Nov 14, 2026, 5:09 AM EST
Completed Phase 1 Interventional Results available

A Pharmacokinetics (PK) Study to Investigate the Effect of Rifampin on PK of Vemurafenib (Zelboraf)

NCT01765543
View directory record Official record
Conditions
Malignant Melanoma, Neoplasms
Interventions
Rifampin, Vemurafenib
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
4
States / cities
Rogers, Arkansas • Pleasant Hill, California • Middletown, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2016 · Synced Nov 14, 2026, 5:09 AM EST